Daré Bioscience, Inc. (DARE): Price and Financial Metrics

Daré Bioscience, Inc. (DARE): $0.36

0.01 (+1.71%)

POWR Rating

Component Grades








Add DARE to Watchlist
Sign Up

Industry: Biotech




#155 of 363

in industry

DARE Price/Volume Stats

Current price $0.36 52-week high $1.40
Prev. close $0.35 52-week low $0.28
Day low $0.34 Volume 209,400
Day high $0.36 Avg. volume 264,690
50-day MA $0.41 Dividend yield N/A
200-day MA $0.77 Market Cap 35.09M

DARE Stock Price Chart Interactive Chart >

Daré Bioscience, Inc. (DARE) Company Bio

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company intends to develop therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single application that completed Phase 3 clinical trials; Ovaprene, a hormone-free, monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone replacement therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214 injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is based in San Diego, California.

DARE Latest News Stream

Event/Time News Detail
Loading, please wait...

DARE Latest Social Stream

Loading social stream, please wait...

View Full DARE Social Stream

Latest DARE News From Around the Web

Below are the latest news stories about DARE BIOSCIENCE INC that investors may wish to consider to help them evaluate DARE as an investment opportunity.

20 Countries with the Highest Teenage Pregnancy Rates

In this article, we will be navigating through adolescent fertility across the world while covering the 20 countries with the highest teenage pregnancy rates. If you wish to skip our detailed analysis, you can move directly to the 5 Countries with the Highest Teenage Pregnancy Rates. Adolescent Pregnancy Across the Globe Early pregnancy and motherhood […]

Yahoo | November 23, 2023

Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs

Partnership Aims to Advance Daré’s Reproductive Health Portfolio in a Timely and Capital Efficient MannerSAN DIEGO and MORRISVILLE, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Premier Research International, LLC, a global clinical research, product development, and consulting company, today announced that the companies extended their partnership agreement under which Premier Research will continue to provide on an exclu

Yahoo | November 20, 2023

Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced that an overview of the preliminary efficacy findings from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% (Sildenafil Cream) in women with female sexual arousal disorder (FSAD) will be presented at the upcoming

Yahoo | November 13, 2023

Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2023 Earnings Call Transcript

Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2023 Earnings Call Transcript November 9, 2023 Daré Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.1. Operator: Welcome to the conference hosted by Daré Bioscience to Review the Company’s Third Quarter Financial Results and to provide a General Business Update. This call is being recorded. My […]

Yahoo | November 10, 2023

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO™: receipt of $1.8 million triggered by achievement of first commercial milestone under license agreement with OrganonOvaprene®: commencement of pivotal Phase 3 contraceptive efficacy studySildenafil Cream, 3.6%: end-of-Phase 2 meeting with FDADARE-PDM1: Phase 1 clinical study topline data SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health i

Yahoo | November 9, 2023

Read More 'DARE' Stories Here

DARE Price Returns

1-mo -7.24%
3-mo -45.45%
6-mo -63.61%
1-year -61.71%
3-year -76.00%
5-year N/A
YTD -56.63%
2022 -58.50%
2021 49.25%
2020 63.41%
2019 15.49%
2018 -67.13%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!